This round would be used to scale Lucence’s operations in terms of clinical trials and marketing across Asia and North America.
Lucence Diagnostics, a startup for molecular biology that develops non-invasive cancer testing using genomics, today announced that it has raised a Series A of $20 million, led by IHH Healthcare, one of the largest integrated private healthcare groups in the world.
This round brings the total raised by Lucence so far to $29.2 million, together with its seed funding.
Sanomics, Prenetics, Guardant and Grail are other companies that have developed cancer risk screening tests and signs. The differentiators of Lucence include their patented amplicon sequencing which searches for specific genomic areas for abnormalities and cancer-related mutations. The company describes its tests as a’ Swiss Army ‘ knife, which can also be used to scan, diagnose, pick treatments and control cancer.